Cargando…
P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429144/ http://dx.doi.org/10.1097/01.HS9.0000848836.01685.87 |
| _version_ | 1784779344541908992 |
|---|---|
| author | Saraf, S. Brown, R. C. Hagar, R. W. Idowu, M. Osunkwo, I. Kalfa, T. A. Kuypers, F. A. Geib, J. Schroeder, P. Wu, E. Kelly, P. Telen, M. J. |
| author_facet | Saraf, S. Brown, R. C. Hagar, R. W. Idowu, M. Osunkwo, I. Kalfa, T. A. Kuypers, F. A. Geib, J. Schroeder, P. Wu, E. Kelly, P. Telen, M. J. |
| author_sort | Saraf, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429144 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94291442022-08-31 P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH Saraf, S. Brown, R. C. Hagar, R. W. Idowu, M. Osunkwo, I. Kalfa, T. A. Kuypers, F. A. Geib, J. Schroeder, P. Wu, E. Kelly, P. Telen, M. J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429144/ http://dx.doi.org/10.1097/01.HS9.0000848836.01685.87 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Saraf, S. Brown, R. C. Hagar, R. W. Idowu, M. Osunkwo, I. Kalfa, T. A. Kuypers, F. A. Geib, J. Schroeder, P. Wu, E. Kelly, P. Telen, M. J. P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_full | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_fullStr | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_full_unstemmed | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_short | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_sort | p1495: etavopivat treatment for up to 12 weeks in patients with sickle cell disease is well tolerated and improves red blood cell health |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429144/ http://dx.doi.org/10.1097/01.HS9.0000848836.01685.87 |
| work_keys_str_mv | AT sarafs p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT brownrc p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT hagarrw p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT idowum p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT osunkwoi p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT kalfata p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT kuypersfa p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT geibj p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT schroederp p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT wue p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT kellyp p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT telenmj p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth |